We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Retina Protein Antibodies Used As Kidney Cancer Marker

By LabMedica International staff writers
Posted on 28 Jan 2019
Renal cell carcinoma (RCC) is the second-most common uronephrological cancer. More...
In the absence of specific symptoms, early diagnosis of RCC is challenging. Monitoring of the aberrant expression of tumor-associated antigens (TAAs) and related autoantibody response is considered as a novel approach of RCC diagnostics.

The initial stages of kidney cancer have no signs or specific symptoms, and therefore patients often get diagnosed with kidney cancer when it has already metastasized. At this point, the doctors make prognosis not about the possibility of recovery, but about a patient's life expectancy. Cancerous cells are the cells with considerable deviations in their behavior, such as abnormal division, development, or protein synthesis.

A large team of scientists based at the Sechenov First Moscow State Medical University (Moscow, Russia) and their German colleagues examined the aberrant expression of arrestin-1 in renal tumors, to investigate the possible epigenetic mechanism underlying arrestin-1 expression, and to assess the frequency of anti-arrestin-1 autoantibody response.

The investigators used immunohistochemistry to assess the presence of arrestin-1 in primary tumors and metastases of 39 patients with RCC and renal oncocytoma. Bisulfite sequencing was employed to analyze the methylation status of the promoter of the S-antigen (SAG) gene encoding arrestin-1. Western blot analysis was performed to detect autoantibodies against arrestin-1 in serum samples of 36 RCC and oncocytoma patients.

Arrestin-1 was found to be expressed in 58.7% of cases of RCC and 90% of cases of renal oncocytoma cells, while being absent in healthy kidney. The expression of arrestin-1 in RCC metastases was more prominent than in primary tumors. Hypomethylation of the SAG gene promoter is unlikely to be the mechanism for the aberrant expression of arrestin-1. Autoantibodies against arrestin-1 were detected in sera of 75% of RCC patients.

All subtypes of kidney tumors synthesize arrestin-1, which makes this method inefficient for differential diagnostics. However, due to its high sensitivity to benign growths, the method helps diagnose a disease on early stages when the chances for recovery are at the highest. The diagnostic procedure is reduced to simple blood test for the antibodies to arrestin-1 instead of a biopsy that is technically complicated and painful for a patient.

Andrey A. Zamyatnin Jr., PhD, DSc, a senior author of the study, said, “The discovery of arrestin-1 synthesis in cases of kidney cancer suggests the possibility of developing anti-cancer vaccines on the basis of this protein in the near future.” The study was published in the February 2019 edition of the journal Biochimie.

Related Links:
Sechenov First Moscow State Medical University


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.